Crohn's disease

Ustekinumab Shows Short-Term Benefit for Fistulising Perianal Crohn's Disease in Small Randomized Trial

A randomized trial found ustekinumab significantly improved combined clinical and radiological remission at week 12 vs placebo in fistulising perianal Crohn's disease, though long-term outcomes were less clear.